Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
74.48
-0.65 (-0.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Ionis to hold fourth quarter and full year 2024 financial results webcast
February 05, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
January 23, 2025
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA
From
Biogen Inc.
Via
GlobeNewswire
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
↗
January 15, 2025
Via
Benzinga
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
↗
January 07, 2025
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.
Via
Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
↗
December 20, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
↗
November 07, 2024
Via
Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
↗
November 07, 2024
Via
Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
↗
January 07, 2025
One analyst says the six-month study was too short and the benefits could appear over time.
Via
Investor's Business Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
↗
January 03, 2025
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Via
Benzinga
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
↗
December 20, 2024
Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
November 12, 2024
Via
Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
↗
October 31, 2024
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
↗
September 26, 2024
Via
Benzinga
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
↗
August 26, 2024
Via
Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
↗
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via
Investor's Business Daily
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
October 08, 2024
From
Biogen Inc.
Via
GlobeNewswire
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
September 10, 2024
Via
Benzinga
12 Analysts Have This To Say About Ionis Pharmaceuticals
↗
August 02, 2024
Via
Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
↗
July 16, 2024
Via
Benzinga
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
↗
June 27, 2024
Via
Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
↗
September 10, 2024
Via
Benzinga
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
September 04, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
September 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
↗
June 03, 2024
Via
Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
↗
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
↗
July 22, 2024
Biogen previously decided against opting into Ionis' Angelman program.
Via
Investor's Business Daily
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
June 24, 2024
Via
Benzinga
Masters In Trading - Saturday, June 22
↗
June 22, 2024
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.
Via
Talk Markets
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
↗
May 31, 2024
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.
Via
Benzinga
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
↗
May 31, 2024
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
